BioMarin acquires world rights to Kuvan (sapropterin dihydrochloride), excluding Japan, and to pegvaliase from Merck Serono as treatments for PKU
BioMarin Pharmaceutical has announced that it has acquired all global rights to Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono. Previously, BioMarin had exclusive rights to Kuvan in the United States and Canada and to pegvaliase in the United States and Japan.
Under the terms of the transaction, BioMarin will now have exclusive worldwide rights to Kuvan and pegvaliase with the exception of Kuvan in Japan. Approved in 2007 in the US, Kuvan is a commercialised product for the treatment of patients with phenylketonuria (PKU). Pegvaliase is currently in registration-enabling pivotal studies as a potential therapeutic option for adult patients with phenylketonuria.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins